Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...
Hosted on MSN

MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now?

・Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...
Zacks Investment Research on MSN

Novavax (NVAX) up 10.4% since last earnings report: Can it continue?

A month has gone by since the last earnings report for Novavax (NVAX). Shares have added about 10.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
The Business Journals

Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Beyond its Covid-19 vaccine ...
The Business Journals

Novavax shareholder Shah Capital urges vaccine maker to explore sale amid market struggles

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 2 min It’s the second time the firm ...
AOL

As FDA delays Novavax' COVID vaccine approval, patients fight back

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F.
Medical Xpress

FDA gives full approval to Novavax COVID shot for high-risk groups

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain people. The vaccine is now approved for adults aged 65 and older, or for ...